ChemGenex Announces Publication Confirming Activity of Ceflatonin® in T315I-Positive CML
this is what their current pivotal study is all about. No drug has done this before
Overview
---------------------------------------
ChemGenex announced the publication of a report in the prestigious Nature publication Leukemia confirming the positive clinical activity of the company’s lead compound, Ceflatonin® against Gleevec®-resistant, chronic myeloid leukemia (CML) associated with the T315I Bcr-Abl mutation.
The publication by Dr. Laurence Legros of the Hôpital Archet, Nice, France and colleagues describes the treatment with Ceflatonin (homoharringtonine, HHT) of a Gleevec-resistant, chronic-phase CML patient with the T315I Bcr-Abl mutation. The authors report that the patient experienced a 50 percent reduction of T315I Bcr-Abl levels within 2.5 months of treatment initiation, and the complete disappearance of the mutation within 5.5 months of treatment. Complete hematological response (CHR) was achieved after three cycles of therapy.
---------------------------------------------------
Publication Details:
BCR-ABLT315I transcript disappearance in an Imatinib-resistant CML patient treated with Homoharringtonine: A new therapeutic challenge? Leukemia advanced online publication May 31, 2007.
Laurence Legros1, Sandrine Hayette2, Franck E. Nicolini3, Sophie Raynaud4, Kaddour Chabane2, Jean-Pierre Magaud2, Jill-Patrice Cassuto1, Mauricette Michallet3
1 Hematology Department, Hôpital Archet 1, 06202 Nice, France;
2 Laboratory for cytogenetics and molecular biology and EA3737, Centre Hospitalier Lyon Sud, 69495 Pierre-Bénite, France;
3 Hematology Department, Hôpital Edouard Herriot, 5 place d’Arsonval 69437 Lyon, France;
4 Hematology Laboratory, Hôpital Archet 2, 06202 Nice, France.
---------------------------------------------------
For full press release please go to
www.chemgenex.com
